Rosetta Genomics to Present at Source Capital's 2016 Disruptive Growth & Healthcare Conference

PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company will be participating at Source Capital’s 2016 Disruptive Growth & Healthcare Conference taking place February 10-11, 2016 in New York City. Kenneth A. Berlin, Chief Executive Officer of Rosetta Genomics, will deliver the corporate presentation at 11:15 a.m. Eastern time on February 11th.

Mr. Berlin’s slide presentation will be available on the Company’s website at www.rosettagx.com.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based and other molecular diagnostics. Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Through the acquisition of PersonalizeDx, the Company now offers core FISH, IHC and PCR-based testing capabilities and partnerships in Pathology, Oncology and Urology that provide additional content and platforms that complement Rosetta’s microRNA and Next-Gen Sequencing offerings. RosettaGX Reveal™, a Thyroid microRNA Classifier for the diagnosis of indeterminate thyroid FNA smears, as well as the full RosettaGX™ portfolio of cancer testing services are commercially available through the Company’s Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs, respectively. For more information visit www.rosettagx.com.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects including, but not limited to statements relating to Rosetta Genomics having a best-in-class FISH testing program, Rosetta Genomics’ testing turnaround times, Rosetta Genomics enhancing oncologist’s treatment options and Rosetta Genomics achieving New York State approval for any or all of its tests, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2014 as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160208005253/en/

Rosetta Genomics:
Ken Berlin, 267-298-1159
President & CEO
[email protected]
or
Rosetta Genomics Investors:
LHA
Anne Marie Fields, 212-838-3777
[email protected]

Source: Rosetta Genomics Ltd.

You May Also Be Interested In

• GXO Logistics, Inc. (GXO) Launches Notes Offering
• Gaucho Group Holdings Inc. (VINO) Receives Nasdaq Non-compliance Notice
• Centessa Pharmaceuticals (CNTA) Announces Pricing of $100 Million Public Offering of American Depositary Shares